vs

Side-by-side financial comparison of Pulmonx Corp (LUNG) and PRO DEX INC (PDEX). Click either name above to swap in a different company.

Pulmonx Corp is the larger business by last-quarter revenue ($20.6M vs $18.7M, roughly 1.1× PRO DEX INC). PRO DEX INC runs the higher net margin — 11.7% vs -66.3%, a 78.0% gap on every dollar of revenue. On growth, PRO DEX INC posted the faster year-over-year revenue change (11.1% vs -8.7%). Over the past eight quarters, PRO DEX INC's revenue compounded faster (14.3% CAGR vs -0.5%).

Pulmonx Corp is a global medical tech firm focused on interventional pulmonology solutions. It develops minimally invasive endobronchial valves to treat severe COPD and emphysema, with products sold across North America, Europe, and Asia-Pacific for patients with advanced lung conditions.

Pro Dex Inc is a precision manufacturing enterprise that produces custom machined components, subassemblies and finished products primarily for medical device original equipment manufacturers, as well as clients in the aerospace and industrial sectors, with its core operating market covering North America.

LUNG vs PDEX — Head-to-Head

Bigger by revenue
LUNG
LUNG
1.1× larger
LUNG
$20.6M
$18.7M
PDEX
Growing faster (revenue YoY)
PDEX
PDEX
+19.8% gap
PDEX
11.1%
-8.7%
LUNG
Higher net margin
PDEX
PDEX
78.0% more per $
PDEX
11.7%
-66.3%
LUNG
Faster 2-yr revenue CAGR
PDEX
PDEX
Annualised
PDEX
14.3%
-0.5%
LUNG

Income Statement — Q1 FY2026 vs Q2 FY2026

Metric
LUNG
LUNG
PDEX
PDEX
Revenue
$20.6M
$18.7M
Net Profit
$-13.7M
$2.2M
Gross Margin
77.9%
30.8%
Operating Margin
-40.9%
17.5%
Net Margin
-66.3%
11.7%
Revenue YoY
-8.7%
11.1%
Net Profit YoY
5.5%
7.2%
EPS (diluted)
$-0.33
$0.66

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LUNG
LUNG
PDEX
PDEX
Q1 26
$20.6M
Q4 25
$22.6M
$18.7M
Q3 25
$21.5M
$18.5M
Q2 25
$23.9M
$17.5M
Q1 25
$22.5M
$17.4M
Q4 24
$23.8M
$16.8M
Q3 24
$20.4M
$14.9M
Q2 24
$20.8M
$15.0M
Net Profit
LUNG
LUNG
PDEX
PDEX
Q1 26
$-13.7M
Q4 25
$-10.4M
$2.2M
Q3 25
$-14.0M
$4.7M
Q2 25
$-15.2M
$1.2M
Q1 25
$-14.4M
$3.3M
Q4 24
$-13.2M
$2.0M
Q3 24
$-14.1M
$2.5M
Q2 24
$-15.3M
$1.6M
Gross Margin
LUNG
LUNG
PDEX
PDEX
Q1 26
77.9%
Q4 25
77.6%
30.8%
Q3 25
74.7%
29.0%
Q2 25
72.1%
19.9%
Q1 25
72.5%
33.3%
Q4 24
74.0%
30.2%
Q3 24
73.7%
34.6%
Q2 24
73.7%
27.2%
Operating Margin
LUNG
LUNG
PDEX
PDEX
Q1 26
-40.9%
Q4 25
-43.8%
17.5%
Q3 25
-66.9%
16.8%
Q2 25
-62.0%
7.7%
Q1 25
-64.6%
20.9%
Q4 24
-56.5%
16.0%
Q3 24
-69.3%
20.2%
Q2 24
-75.2%
15.6%
Net Margin
LUNG
LUNG
PDEX
PDEX
Q1 26
-66.3%
Q4 25
-46.1%
11.7%
Q3 25
-64.9%
25.3%
Q2 25
-63.6%
6.8%
Q1 25
-64.1%
18.8%
Q4 24
-55.4%
12.1%
Q3 24
-69.4%
16.6%
Q2 24
-73.7%
10.6%
EPS (diluted)
LUNG
LUNG
PDEX
PDEX
Q1 26
$-0.33
Q4 25
$-0.25
$0.66
Q3 25
$-0.34
$1.40
Q2 25
$-0.38
$0.33
Q1 25
$-0.36
$0.98
Q4 24
$-0.33
$0.61
Q3 24
$-0.36
$0.75
Q2 24
$-0.39
$0.44

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LUNG
LUNG
PDEX
PDEX
Cash + ST InvestmentsLiquidity on hand
$61.6M
$6.1M
Total DebtLower is stronger
$37.3M
Stockholders' EquityBook value
$45.8M
$41.6M
Total Assets
$120.0M
$62.3M
Debt / EquityLower = less leverage
0.82×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LUNG
LUNG
PDEX
PDEX
Q1 26
$61.6M
Q4 25
$69.8M
$6.1M
Q3 25
$76.5M
$10.1M
Q2 25
$75.5M
$6.8M
Q1 25
$74.6M
$5.5M
Q4 24
$70.9M
$4.7M
Q3 24
$63.3M
$7.8M
Q2 24
$63.5M
$6.8M
Total Debt
LUNG
LUNG
PDEX
PDEX
Q1 26
$37.3M
Q4 25
$37.1M
Q3 25
$37.1M
Q2 25
$37.1M
$15.4M
Q1 25
$37.2M
Q4 24
$37.2M
Q3 24
$37.2M
Q2 24
$37.2M
$12.0M
Stockholders' Equity
LUNG
LUNG
PDEX
PDEX
Q1 26
$45.8M
Q4 25
$54.1M
$41.6M
Q3 25
$60.0M
$41.5M
Q2 25
$69.1M
$36.6M
Q1 25
$77.7M
$35.3M
Q4 24
$85.8M
$31.8M
Q3 24
$93.9M
$30.9M
Q2 24
$101.2M
$30.9M
Total Assets
LUNG
LUNG
PDEX
PDEX
Q1 26
$120.0M
Q4 25
$129.3M
$62.3M
Q3 25
$138.3M
$64.3M
Q2 25
$147.2M
$61.2M
Q1 25
$150.7M
$64.3M
Q4 24
$162.8M
$60.4M
Q3 24
$167.4M
$54.3M
Q2 24
$172.6M
$52.5M
Debt / Equity
LUNG
LUNG
PDEX
PDEX
Q1 26
0.82×
Q4 25
0.69×
Q3 25
0.62×
Q2 25
0.54×
0.42×
Q1 25
0.48×
Q4 24
0.43×
Q3 24
0.40×
Q2 24
0.37×
0.39×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LUNG
LUNG
PDEX
PDEX
Operating Cash FlowLast quarter
$3.6M
Free Cash FlowOCF − Capex
$3.5M
FCF MarginFCF / Revenue
18.8%
Capex IntensityCapex / Revenue
0.4%
Cash ConversionOCF / Net Profit
1.63×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LUNG
LUNG
PDEX
PDEX
Q1 26
Q4 25
$-7.1M
$3.6M
Q3 25
$-8.2M
$2.3M
Q2 25
$-3.9M
$-173.0K
Q1 25
$-13.2M
$754.0K
Q4 24
$-6.7M
$-4.2M
Q3 24
$-7.2M
$1.9M
Q2 24
$-5.8M
$1.0M
Free Cash Flow
LUNG
LUNG
PDEX
PDEX
Q1 26
Q4 25
$-7.1M
$3.5M
Q3 25
$-8.3M
$2.2M
Q2 25
$-4.0M
Q1 25
$-13.5M
$574.0K
Q4 24
$-6.8M
$-4.7M
Q3 24
$-7.7M
$1.5M
Q2 24
$-6.2M
FCF Margin
LUNG
LUNG
PDEX
PDEX
Q1 26
Q4 25
-31.4%
18.8%
Q3 25
-38.4%
11.9%
Q2 25
-16.6%
Q1 25
-60.0%
3.3%
Q4 24
-28.8%
-27.9%
Q3 24
-37.6%
9.8%
Q2 24
-30.0%
Capex Intensity
LUNG
LUNG
PDEX
PDEX
Q1 26
Q4 25
0.1%
0.4%
Q3 25
0.4%
0.5%
Q2 25
0.2%
Q1 25
1.3%
1.0%
Q4 24
0.5%
3.2%
Q3 24
2.0%
2.9%
Q2 24
2.3%
Cash Conversion
LUNG
LUNG
PDEX
PDEX
Q1 26
Q4 25
1.63×
Q3 25
0.49×
Q2 25
-0.14×
Q1 25
0.23×
Q4 24
-2.03×
Q3 24
0.77×
Q2 24
0.66×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons